← Leaderboards
Yohannes T Ghebre
University Of Texas Hlth Science Center
$4,651,148
Attributed
$4,651,148
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $748.3K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,651,148 · 4
By mechanism
R01$3,616,723 · 2
K01$682,425 · 1
R56$352,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsFda ApprovedMolecularLungPulmonary FibrosisTissuesAnimalsCollagenPharmaceutical PreparationsMouse ModelFibrosisEtiologyFibroblastsSmall MoleculeHigh Throughput ScreeningDepositionBaseInnovationBleomycinInflammationLung InflammationProton Pump InhibitorsBinding SitesFibrogenesis
Grant awards (16)
Repurposing esomeprazole for the treatment of scleroderma$511,584
R01 · FY2025 · AR · contact PI
Repurposing esomeprazole for the treatment of scleroderma$534,965
R01 · FY2024 · AR · contact PI
Repurposing esomeprazole for the treatment of scleroderma$532,463
R01 · FY2022 · AR · contact PI
Repurposing esomeprazole for the treatment of scleroderma$56,461
R01 · FY2022 · AR · contact PI
Combination of PPI and pirfenidone to enhance antifibrotic efficacy$396,249
R01 · FY2021 · HL · contact PI
Combination of PPI and pirfenidone to enhance antifibrotic efficacy$1
R01 · FY2021 · HL · contact PI
Combination of PPI and pirfenidone to enhance antifibrotic efficacy$396,250
R01 · FY2020 · HL · contact PI
Repurposing esomeprazole for the treatment of scleroderma$352,000
R56 · FY2020 · AR · contact PI
Combination of PPI and pirfenidone to enhance antifibrotic efficacy$396,250
R01 · FY2019 · HL · contact PI
Combination of PPI and pirfenidone to enhance antifibrotic efficacy$396,250
R01 · FY2018 · HL · contact PI
Combination of PPI and pirfenidone to enhance antifibrotic efficacy$396,250
R01 · FY2017 · HL · contact PI
DDAH As a Novel Target in Pulmonary Fibrosis$143,775
K01 · FY2017 · HL · contact PI
DDAH As a Novel Target in Pulmonary Fibrosis$143,775
K01 · FY2016 · HL · contact PI
DDAH As a Novel Target in Pulmonary Fibrosis$131,625
K01 · FY2015 · HL · contact PI
DDAH As a Novel Target in Pulmonary Fibrosis$131,625
K01 · FY2014 · HL · contact PI
DDAH As a Novel Target in Pulmonary Fibrosis$131,625
K01 · FY2013 · HL · contact PI